Granules India Limited today announced that its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), located in Hyderabad (FEI: 3030495702), has received U.S. Food and Drug Administration (FDA) approval for a product that was the subject of a Pre- Approval Inspection (PAI) conducted between
The healthcare and life sciences sectors are now bracing for global ripple effects as the Trump administration, under President Donald J. Trump’s second term, enforces a new round of tariffs targeting imports from key trade partners, including India and China. The proposed 25% tariff on
n a landmark development for global cancer care, Cipla Limited (BSE: 500087; NSE: CIPLA EQ), a leading global pharmaceutical company, today announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for
In a move that has sent shockwaves through the Indian medical device industry, former U.S. President Donald Trump has imposed a 26% reciprocal tariff on medical device exports from India. This decision, aimed at correcting perceived trade imbalances and promoting domestic manufacturing in the U.S.,
Gaurav Agarwal, Co-Chair of the Medical Devices Committee at PHDCCI, highlights the balanced approach of India’s Central Drugs Standard Control Organisation (CDSCO) in eliminating clinical trial waivers for in-vitro diagnostics (IVDs). This decision ensures both patient safety and fosters innovation within the healthcare sector. India's
Global pharma major Lupin Limited (Lupin) today announced that its Unit-2 manufacturing facility located in Mandideep, India, has successfully completed a GMP inspection by the United States Food and Drug Administration (U.S. FDA). The inspection was conducted from August 7 to August 11, 2023 and concluded
